Cerus (NASDAQ:CERS) Shares Pass Above 200 Day Moving Average – Here’s What Happened

Cerus Corporation (NASDAQ:CERS) shares crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.65 and traded as high as $2.47. Cerus shares last traded at $2.46, with a volume of 567,651 shares.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on CERS. TD Cowen restated a “buy” rating on shares of Cerus in a research report on Monday, January 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cerus in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Cerus from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $4.00.

Cerus Price Performance

The company has a quick ratio of 1.29, a current ratio of 1.89 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $472.54 million, a PE ratio of -30.75 and a beta of 1.52. The firm’s 50 day simple moving average is $2.09 and its 200 day simple moving average is $1.65.

Cerus (NASDAQ:CERS) last released its earnings results on Thursday, November 6th. The biotechnology company reported $0.00 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.02. The firm had revenue of $60.24 million during the quarter, compared to analyst estimates of $55.12 million. Cerus had a negative net margin of 8.01% and a negative return on equity of 27.58%. As a group, research analysts anticipate that Cerus Corporation will post -0.08 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of CERS. CWM LLC raised its holdings in shares of Cerus by 6.8% in the fourth quarter. CWM LLC now owns 129,084 shares of the biotechnology company’s stock worth $266,000 after buying an additional 8,178 shares during the period. Bingham Private Wealth LLC bought a new position in Cerus in the 4th quarter valued at $40,000. SG Americas Securities LLC grew its position in Cerus by 52.9% in the 4th quarter. SG Americas Securities LLC now owns 61,268 shares of the biotechnology company’s stock valued at $126,000 after acquiring an additional 21,206 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in Cerus by 5.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,676,279 shares of the biotechnology company’s stock worth $3,453,000 after purchasing an additional 92,577 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its position in shares of Cerus by 8.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 81,556 shares of the biotechnology company’s stock worth $169,000 after purchasing an additional 6,094 shares during the last quarter. Institutional investors own 78.37% of the company’s stock.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.